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Abstract
Context: Obesity is a multifactorial disorder, that is, a disease determined by the combined effect
of genes and environment. In this context, polygenic approaches are needed.
Objective: To investigate the possibility of the existence of a crosstalk between the CALPAIN 10
homologue CALPAIN 5 and nuclear receptors of the peroxisome proliferator-activated receptors
family.
Design: Cross-sectional, genetic association study and gene-gene interaction analysis.
Subjects: The study sample comprise 1953 individuals, 725 obese (defined as body mass index ≥
30) and 1228 non obese subjects.
Results: In the monogenic analysis, only the peroxisome proliferator-activated receptor delta
(PPARD) gene was associated with obesity (OR = 1.43 [1.04–1.97], p = 0.027). In addition, we have
found a significant interaction between CAPN5 and PPARD genes (p = 0.038) that reduces the risk
for obesity in a 55%.
Conclusion: Our results suggest that CAPN5 and PPARD gene products may also interact in vivo.
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Introduction
Obesity, which is among of the most hereditable human
conditions (45–75%), is, with few exceptions, a polygenic
disorder determined by an unknown number of genes
with mild to moderate individual effects that also inter-
acts with the environment to produce the phenotype. The
importance of the genetic component in obesity has been
assessed by the observation of familial aggregation, prev-
alence differences among ethnic groups and concordance
rates in twin studies [1]. Association analysis has been the
more successful strategy for the identification of these
genetic factors, but these studies are not always replicated
in subsequent analyses and only a small proportion of
these genes have been consistently associated with the dis-
ease [2]. This situation is mainly due to small single gene
effects, reason why, genetic association analysis can be
strongly influenced by sample size, population structure
and allele frequency. Thus, the polygenic approach is aris-
ing as the next landmark for the study of common com-
plex diseases [3,4].
The peroxisome proliferator-activated receptors (PPARs)
belong to a nuclear receptor (NR) superfamily of ligand-
inducible transcription factors that form functional com-
plexes with the retinoid × receptors (RXRs). Three sub-
types, alpha (α), gamma (γ) and delta (δ), have been
identified. PPARα (PPARA) is a regulator of fatty acid oxi-
dation [5], whereas PPARγ (PPARG) mainly functions as a
regulator of adipogenesis [6]. PPARG is expressed at adi-
pose tissue, macrophages and muscle where it regulates
glucose metabolism. Knockout mice for Pparg are embry-
onic lethal, but specific deletion of the PPARG gene in fat
and muscle has been shown to cause insulin resistance
[7,8]. PPARG contributes to the control of energy expend-
iture by the induction of a futile metabolic cycle in the
mitochondria mediated by glycerol kinase and the uncou-
pling proteins (UCPs), which are transcriptionally regu-
lated by PPARG [9]. Genetic studies have also greatly
contributed to corroborate the role of PPARG  in the
pathogenesis of metabolic syndrome related phenotypes:
the Pro12Ala polymorphism of PPARG  gene has been
confirmed to be associated with greater body mass index
(BMI) and insulin sensitivity in the obese subgroup in a
recent meta-analysis with more than 32.000 individu-
als[10].
In the last few years, PPARδ (PPARD) has been shown to
have a critical role in the regulation of energy metabolism
[11]. Increased Ppard expression in adipose tissue in mice
has a protective effect against elevated adiposity and
serum lipid levels [12]. The activation of PPARD results in
the increased expression of genes involved in lipid uptake,
fatty acid oxidation and uncoupling proteins, highlight-
ing the PPARD prominent role in mitochondrial activity
[13,14]. PPARD gene variants have been associated with
obesity [15-17], although some authors have failed to rep-
licate this finding [18-21]. Recent reports have associated
PPARD polymorphisms with the effectiveness of cardio-
vascular fitness, demonstrating the pivotal role of PPARD
gene variants in mitochondrial function and, in conse-
quence, in weight control [22,23].
The calpain family comprises a heterogeneous group of
cysteine proteases with a broad expression pattern that
includes multiple isoforms that are both ubiquitous and
tissue specific. Calpains are involved in a variety of cal-
cium-regulated cellular processes, such as signal transduc-
tion, cell proliferation and differentiation, and apoptosis
[24]. The calpain role in apoptosis is related to the prote-
olytic cleavage of the proapoptotic Bax protein, a member
of the Bcl-2 family, and the generation of a potent proap-
optotic fragment (Bax/p18), which in turn mediates
cytocrome c release and initiates the apoptotic execution;
this action occurs in the mitochondria, so calpain activity
exists within this cell fraction [25]. Calpain 10 (CAPN10)
is a member of this protease family which is included into
the atypical calpain subgroup, characterized by the
absence of the EF-hand domain distinctive of the classical
calpains and the presence of a so-called T domain homo-
logue of the Caenorhabditis elegans TRA-3 calpain. The
CAPN10 gene was identified as a type 2 diabetes (T2DM)
susceptibility locus by Horikawa et al. [26] and, since then,
has been associated with many other related conditions
such as polycystic ovary syndrome (PCOS), dyslipidemia,
hypertension or increased BMI by different groups [24].
CAPN10 has been related to pancreatic β-cell apoptosis
initiated by the fatty acid palmitate [27]. Later on,
CAPN10 protein was identified within the mitochondria:
the overexpression of mitochondrial CAPN10 results in
mitochondrial swelling and autophagy through the cleav-
age of Complex I subunits and activation of mitochon-
drial permeability transition (MPT) [28]. The CAPN10
homologue calpain 5 (CAPN5), was firstly analysed in
humans by our group [29,30]. In these studies, we found
that specific CAPN5 haplotypes could modify the risk of
developing metabolic syndrome and PCOS, a common
endocrine disorder in women of reproductive age in
which all components of metabolic syndrome are fre-
quent. CAPN5 haplotypes were also shown to be associ-
ated with diastolic blood pressure and cholesterol levels
and a trend for BMI association was observed.
Interestingly, some reports have described proteolytic
activity of calpains over the PPARs partners in signalling
RXRs at the mitochondria [31,32] and over PPARG at the
adipose tissue [33]. On the other hand, transcriptional
regulation of calpain activity by PPARG has been also
described [34].Cardiovascular Diabetology 2008, 7:23 http://www.cardiab.com/content/7/1/23
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Our main objective was to investigate the possibility of
the existence of a crosstalk between the CAPN10 homo-
logue CAPN5 and NRs of the PPAR family. With this pur-
pose, we have selected highly informative polymorphisms
in CAPN5, PPARG and PPARD genes and analysed it in
1953 individuals in relation to the absence or presence of
obesity. Additionally, we have investigated the individual
contributions of these polymorphisms to the obesity phe-
notype. We have found that the PPARD polymorphism is
associated with obesity in our population. We have also
found the existence of genetic interaction between CAPN5
and PPARD genes.
Methods
Population
The study sample comprised 1953 individuals, 725 obese
(defined as BMI ≥ 30) and 1228 non obese subjects
recruited from both a population based study and from
outpatient visits to different hospitals in a multicenter
study as previously described [35,36]. The referral centres
involved in this research are Hospital Universitario de
Valme (Sevilla), Hospital Universitario Ramon y Cajal
(Madrid), and Hospital Universitario San Carlos
(Madrid). Informed written consent was obtained from
all study participants. The study protocol was designed in
accordance with institutional guidelines for human
research and was approved by the Ethics Committees of
all referral centres.
Polymorphisms
In order to perform genetic interaction analyses, we have
selected three frequent and highly informative polymor-
phisms (heterozygosity ≥ 40%) within CAPN5
(rs7102149 G/A), PPARG (rs2938392 C/T) and PPARD
(rs2076167 A/G, N798N). Since in our previous study the
genetic association analysis of four CAPN5  polymor-
phisms with BMI was not conclusive, we have selected a
polymorphism at the second intron of the gene, close to
the recombination hot spot observed in this gene region
that defines the two haplotypic blocks analysed in our
prior report [30]. This polymorphism has been found to
be expressed in two CAPN5 mRNAs where it is predicted
to encode a tryptophan residue in the wild type state (G,
TGG) and a stop codon in the polymorphic state (A,
TAG). The PPARG polymorphism is located at the fifth
intron of the gene in the same disequilibrium block than
the Pro12Ala polymorphism using HapMap data, but
have a higher allelic frequency and heterozygosity, being
for these reasons more informative than Pro12Ala. The
selected  PPARD  polymorphism encodes an asparagine
(Asn) residue in the sixth exon of the gene.
Genotyping
We obtained 5 ml of peripheral blood from all patients
and controls to isolate germline DNA from leukocytes.
DNA extraction was performed in a MagNa Pure LC
Instrument (Roche Diagnostics, Indianapolis, IN, USA)
according to the manufacturer's instructions. To perform
polymerase chain reactions (PCRs), we prepared aliquots
of DNA at a concentration of 5 ng/μl. The rest of the stock
was cryopreserved at -20°C.
PCR reactions were run on a thermal cycler machine (MJ
Research Inc., Waltman, Masachusetts, USA) using a final
volume of 20 μl. The genotypes were carried out by using
the pyrosequencing technology protocols [37]. The
selected primers for pyrosequencing analysis are shown in
Table S1. The pyrosequencing machine was programmed
in accordance with the manufacturer's recommendation
(Biotage, Uppsala, Sweden).
A 10% of the samples were re-extracted and retyped as an
internal control of the quality of the genotyping with a
concordance rate of > 99%.
Statistical analysis
To analyze deviation from Hardy-Weinberg equilibrium,
we used tests adapted from Sasieni [38] at the online
resource available at the Institute for Human Genetics,
Munich, Germany http://ihg.gsf.de.
Logistic regression analysis was used to calculate individ-
ual and combined gene effects. For testing gene-gene
interactions, we introduced and interaction term within
the logistic regression model along with the univariate
terms. All analyses have been adjusted for age, sex, smok-
ing (defined as present or past history of smoking of at
least five cigarettes per day for a minimum of 5 years),
alcohol consumption (defined as a daily intake of more
than 10 g) and physical activity. Power calculations sug-
gest that we have 90% power at a significance level of 0.05
to detect an OR for obesity of 1.5.
Statement of Ethics
We certify that all applicable institutional and govern-
mental regulations concerning the ethical use of human
volunteers were followed during this research.
Results
Monogenic association analysis
The observed allele frequencies were 0.63 in controls and
0.64 in cases at the CAPN5 locus (p = 0.456), 0.54 in con-
trols and 0.53 in cases at the PPARG locus (p = 0.340) and
0.72 in controls and 0.69 in cases at the PPARD locus,
showing the polymorphic allele at this last gene a slight
over-representation in the obese subgroup (p = 0.021). All
genotype frequencies are in accordance with the Hardy-
Weinberg equilibrium law (p > 0.301) except for the cases
group at the PPARG locus, with a slight deviation from the
expected proportions (p = 0.037).Cardiovascular Diabetology 2008, 7:23 http://www.cardiab.com/content/7/1/23
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In the quantitative genotypic association analysis (Table
1), we didn't observe significant differences at CAPN5 or
PPARG loci, whereas homozygotes for the polymorphic G
allele at the PPARD locus have slightly greater BMI than
individuals carrying at least one A allele (28.88 kg/m2 vs
28.12 kg/m2, p = 0.033).
According to allelic frequencies and quantitative associa-
tion analysis, the homozygous presence of the polymor-
phic G allele at PPARD locus is more common in the obese
subgroup (OR = 1.43 [1.04–1.97], p = 0.027) (Table 2).
No association was observed for the analysed polymor-
phisms at the CAPN5 (p ≥ 0.126) or PPARG (p ≥ 0.199)
genes.
Interaction analysis
We didn't find evidence of interaction between PPARD
and PPARG (p = 0.602), whereas a trend was observed for
PPARG and CAPN5 genes (p = 0.056). Regarding PPARD
and CAPN5 genes, we detected a significant genetic inter-
action between the homozygous presence of the polymor-
phic allele at CAPN5 locus and the wild type at PPARD
locus (CAPN5_AA*PPARD_AA, p = 0.038) (Table 3 and
figure 1). When compared with non carriers of any of the
two genotypes, only the individuals carrying both geno-
types are significantly less frequently obese (OR = 0.55
[0.35–0.85], p = 0.008).
Discussion
The PPARD receptor has a well established role in lipid
metabolism, but its implication in the modulation of
lipid stores is more controversial. Transgenic mice with
targeted activation of Ppard in adipose tissue are resistant
to both high-fat diet-induced and genetically predisposed
(db/db) obesity; treatment of db/db mice with the PPARD
agonist GW501516 also reversed obesity [11]. Several
groups have examined different PPARD  gene polymor-
phism in obesity related traits, half of them with positive
results. All but two of these reports are limited to a SNP
located at the 5'-UTR region of the exon 4 (rs2016520,
referred as T+294C or c.-87T>C); this polymorphism is
located at the linkage disequilibrium (LD) block adjacent
to that of the N798N SNP analysed in the present work
[16-19]. In the other two reports, tag SNPs throughout the
genomic sequence of PPARD gene were explored, but only
one of them obtained positive results [15,20]. The poly-
morphism analysed by our group has only been explored
in the work by Grarup et al. [20], who didn't find associa-
tion with obesity but identified an haplotype consisting of
the rare alleles of this SNP and the rs2076169 polymor-
phism, located upstream in the same LD block, that was
associated with a greater insulin sensitivity. We have not
found evidence of the N798N polymorphism being asso-
ciated with glucose levels or HOMA values in our popula-
tion (data not shown). The identification of genetic
association of PPARD with obesity in our population con-
tributes to the notion that this gene is a candidate gene for
obesity and related phenotypes.
We have not found association of the PPARG selected pol-
ymorphism with obesity in this population. We selected
this polymorphism because is more informative than
Pro12Ala and is in the same LD block. Only two works
have previously analysed the Pro12Ala polymorphism in
Spanish population [39,40]. In one of them, association
with obesity was observed only in men (210 individuals)
whereas in the other report, statistical significance was
only achieved when physical activity was taken into
account. Taken together,PPARG does not seem to be a
major locus for obesity in our population. Regarding insu-
lin sensitivity, we have not found association of this poly-
morphism with fasting insulin levels nor HOMA values.
However, previous studies in Spanish population have
associated the Pro12Ala polymorphism with estimates of
insulin sensitivity [39,41], so we can no rule out PPARG
gene as a genetic factor influencing insulin action in our
population.
The association analysis at the CAPN5 did not contribute
to elucidate if this gene has, per se, a role in obesity, since
we did not found statistical significant differences at this
locus between controls and cases (p ≥ 0.126). Thus, this
polymorphism, which is predicted to encode a stop codon
in one of the CAPN5 mRNAs identified so far, doesn't
seem to be a functional variant involved in obesity.
The most relevant result of our work is the identification
of genetic interaction between CAPN5 and PPARD genes.
The physiological mechanism underlying the observed
interaction is unknown, but we postulate that it could be
related to mitochondrial biology. The existence of calpain
activity in the mitochondria is a well known fact thanks to
the extensive investigations performed in the field of
Table 1: Quantitative association analysis of the selected 
polymorphisms with BMI.
S N P 1 11 22 2P  ( 2 d f )
CAPN5
(rs7102149)
28,11 ± 1.01 28,14 ± 1.01 27,84 ± 1.01 0.552
(0.820) (0.592) (0.281)
PPARG
(rs2938392)
28,27 ± 1.01 27,95 ± 1.01 28,21 ± 1.01 0.289
(0.254) (0.118) (0.534)
PPARD
(rs2076167)
28,12 ± 1.01 28,15 ± 1.01 28,88 ± 1.01 0.103
(0.409) (0.697) (0.033)
Data are means ± std. error. Number in brackets are p values (1 df) 
resulting from the comparison of each genotype against the remaining 
genotypes. CAPN5, allele 1:G, allele 2: A; PPARG, allele 1: C, allele 2: 
T; PPARD, allele 1:A, allele 2: GCardiovascular Diabetology 2008, 7:23 http://www.cardiab.com/content/7/1/23
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apoptosis, one of the more relevant calpain biological
activities. In this way, the CAPN5 homologue, CAPN10,
has been shown to exist within the mitochondria and to
be involved in pancreatic β-cell apoptosis, a process pos-
tulated to underlie the association of this gene with the
insulin resistance phenotype [27,28,42]. On the other
hand, mitochondrial versions of NRs have been identi-
fied, including the PPARG and the thyroid hormone
receptor A (THRA) that is also a RXR partner in signalling,
although the existence of the latter is still a controversial
issue [43]. Moreover, some reports have described proteo-
lytic activity of calpains over members of the PPAR and
RXR families related to the generation of mitochondrial
versions of these receptors that regulate mitochondrial
gene expression [31]. Proteolytic cleavage of RXR by cal-
pains has been also observed in hepatoma cell lines [32].
Recently, a report by Yajima et al. [33] describes that cal-
pain system regulates the differentiation of adult primitive
mesenchymal ST-13 adipocytes through the cleavage of
PPARG. On the other hand, transcriptional regulation of
calpain activity by PPARG has been also described [34]. In
this way, a recent report has shown that the PPARG ago-
nist rosiglitazone reduces μ-calpain activity, normalizing
platelet endothelial cell adhesion molecule-1 levels and
partially restoring platelet sensitivity to nitric oxide syn-
thase inhibition in type 2 diabetic subjects, a mechanism
related to the anti-atherogenic properties of this drug [44].
Although our results regarding CAPN5 and PPARG inter-
action are not conclusive, we can not rule out the possibil-
ity that exits given the statistical trend observed, the
similitude between the PPAR family members and the
existent bibliography. Further analysis in bigger popula-
tions or in other phenotypes besides functional studies
will help to clarify this issue.
The existence of calpain activity over NRs, could exist not
only inside the mitochondria, but also in the nucleus,
being a possible biological explanation for the unusual
presence of proteases into the nucleus; this cellular loca-
tion has been observed for both CAPN5 and CAPN10
among other calpains [45]. Several authors have described
calpain activity over diverse NRs including the androgen
receptor [46,47] and the estrogen receptors (ERs) [48,49].
Interestingly, mitochondrial versions of the ERs have been
also described [43]. Conversely, several NRs modulate the
expression of calpains: retinoids, the ligands for retinoid
acid receptors (RARs), estrogens, that mediates their
action through the estrogen receptors (ERs) and the 1,25-
dihydroxyvitamin D3, which uses the vitamin D receptor
(VDR), have shown to regulate calpain activity [50-54].
Interaction genetic analysis can help to identify genetic
factors that when acting together, modify the risk of suf-
fering from a complex disease and contribute to elucidate
Table 2: Genetic association analysis of CAPN5 and PPARD gene variants with obesity.
Gene Genotype Controls Cases P value OR [CI]
CAPN5
(rs7102149)
GG 498 299 0.899 1.01 [0.85–1.21]
GA 550 332 0.342 1.09 [0.91–1.30]
AA 180 94 0.126 0.82 [0.63–1.06]
PPARG
(rs2938392)
CC 366 215 0.885 0.99 [0.81–1.20]
CT 597 333 0.346 0.92 [0.77–1.01]
TT 265 177 0.199 1.15 [0.93–1.43]
PPARD
(rs2076167)
AA 639 348 0.295 0.91 [0.76–1.09]
AG 494 300 0.843 0.98 [0.81–1.18]
GG 95 77 0.027 1.43 [1.04–1.97]
Table 3: Odds ratio (OR) for obesity in the presence/absence of PPARD_AA and CAPN5_AA genotypes.
PPARD_AA CAPN5_AA Controls Cases OR [CI] P value
- - 502 317 1
- + 87 60 1.06 [0.72–1.56] 0.764
+ - 546 314 0.96 [0.78–1.19] 0.720
+ + 93 34 0.55 [0.35–0.85] 0.008
P value for interaction = 0.038Cardiovascular Diabetology 2008, 7:23 http://www.cardiab.com/content/7/1/23
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the molecular mechanism of the studied disease. This
knowledge could have direct implications in the clinical
management of the patients, heading the pharmacologi-
cal therapy to the most suitable biological process. We
propose that the pathological mechanism of CAPN5 and,
perhaps, its homologue CAPN10, could be related to the
existence of a cross-talk between this calpain and the
RXRs/PPARs nuclear receptors, which are key proteins in
the intermediate metabolism and major pharmacological
targets. For one hand, CAPN5 regulates these NRs levels
and, on the other hand, the NRs regulate CAPN5 level
through the induction/repression of its expression. How-
ever, functional studies are needed to investigate if the
proposed mechanism could be plausible in living cells
and if true, pharmacological implications for PPAR ago-
nist should be explored.
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